Raptor Pharma (RPTP) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Wedbush Upgrades Raptor Pharmaceuticals (RPTP) to Neutral; Huntington's Next Shoe to Drop
November 6, 2015 7:58 AM ESTWedbush upgraded Raptor Pharmaceuticals (NASDAQ: RPTP) from Underperform to Neutral with a price target of $7.00 on valuation but remains negatively biased on Huntington's program.
David Nierengarten commented, "With the failure of RP103 in NASH in September, we expect Huntingtons... More
